enGene Therapeutics (ENGN) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic overview and market opportunity

• Detalimogene is positioned as a next-generation non-viral gene therapy for NMIBC, addressing unmet needs with a 54% complete response rate and best-in-class tolerability and ease of use.

• The NMIBC market is expanding due to increased sequencing of therapies, with most patients treated in community settings seeking efficacy, tolerability, and workflow compatibility.

• Market research indicates a significant patient pool (40,000–75,000 high-risk BCG unresponsive/exposed patients), with payers supportive of new therapies and pricing benchmarks rising to $700,000 per patient annually.

• The market is expected to grow substantially over the next five years, with multiple agents coexisting and patients receiving several lines of therapy.

• Detalimogene's unique attributes—simple storage, administration, and no need for decontamination—make it especially suitable for community practices.

Clinical development and product differentiation

• Detalimogene is a lyophilized, non-viral gene therapy delivering two RIG-I genes and IL-12, with a proprietary sugar-based nanoparticle formulation for stability and ease of use.

• The LEGEND clinical program targets BCG-unresponsive NMIBC patients, showing a 54% CR rate and anticipated 12-month landmark CR of 24–25%, with about half of responders maintaining response at 12 months.

• Tolerability is strong, with low rates of treatment-related adverse events (55%) and dose interruptions (2.4%), trending toward best-in-class.

• A new cohort combining detalimogene with a surfactant bladder rinse (polidocanol) aims to improve efficacy, durability, and reduce dwell time from 60 to 30 minutes, with safety run-in completed and ongoing enrollment.

• Pre-BLA meeting with the FDA is planned, with filing initiation by year-end and potential approval and platform designation expected in 2027.

Financial position and near-term milestones

• Cash reserves stand at $266 million, sufficient to reach key milestones including pivotal data updates, regulatory filings, and potential approval.

• Manufacturing is validated at scale, with product stability supporting broad distribution and ease of integration into clinical practice.

• Upcoming milestones include pivotal data updates in the next quarter, pre-BLA meeting, and BLA filing by year-end.

• The company anticipates providing further efficacy and durability data, especially regarding the surfactant cohort, in Q4 2026.

• Leadership team has a track record of successful product commercialization, supporting confidence in execution.